VYGR241220P12500
- 0.00
- 0.000.00%
Voyager Therapeutics Newsroom
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology
Citigroup Initiates Coverage On Voyager Therapeutics With Buy Rating, Announces Price Target of $12
Voyager Therapeutics Analyst Ratings
Citi Initiates Voyager Therapeutics(VYGR.US) With Buy Rating, Announces Target Price $12
Wedbush Upgrades Voyager Therapeutics(VYGR.US) to Buy Rating, Announces Target Price $11
Express News | Voyager Therapeutics Inc : Wedbush Assumes Coverage With Outperform Vs Neutral Rating; Target Price $11 Vs $7
Express News | Voyager Therapeutics : Candidate Vy1706 Demonstrates Significant Reductions of Tau at Low Doses in Nhp Study; Ind & Cta Filings Anticipated in 2026
Express News | Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease
Not Many Are Piling Into Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Yet As It Plummets 29%
Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)
A Quick Look at Today's Ratings for Voyager Therapeutics(VYGR.US), With a Forecast Between $14 to $30
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?
Q3 2024 Voyager Therapeutics Inc Earnings Call
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Wells Fargo Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $14
Express News | Voyager Therapeutics Inc : Leerink Partners Cuts Target Price to $14 From $15
Voyager Therapeutics: Solid Financial Foundation and Strategic Progress Justify Buy Rating